Systemic inflammation-associated glucocorticoid resistance and outcome of ARDS

Annals of the New York Academy of Sciences

Volumn 1024, Issue , 2004, Pages 24-53

  Meduri, G Umberto ^a,c   Yates, Charles R ^b  

^a Division of Pulmonary   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^c UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

Author keywords

ARDS; Glucocorticoid resistance; GR; HPA axis; Inflammation; NF B

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE; CORTICOTROPIN; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN BINDING PROTEIN; CYTOKINE; DOUBLE STRANDED DNA; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; GLYCOPROTEIN P; HEAT SHOCK PROTEIN 60; HYDROCORTISONE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 6; METHYLPREDNISOLONE; NITRIC OXIDE SYNTHASE; PHOSPHOLIPASE A2; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR AP 1; TUMOR NECROSIS FACTOR ALPHA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CLINICAL TRIAL; CONFERENCE PAPER; DISSEMINATED INTRAVASCULAR CLOTTING; DNA BINDING; DRUG EFFICACY; ENZYME ACTIVITY; FAMILIAL DISEASE; GENE CONTROL; HORMONE RELEASE; HOST RESISTANCE; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; INFLAMMATION; MORPHOLOGY; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PROMOTER REGION; PROTEIN DEGRADATION; RESPIRATORY DISTRESS; SEPSIS; SIGNAL TRANSDUCTION; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 3042706511     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1196/annals.1321.004     Document Type: Conference Paper

References (159)

1. FRANCHIMONT, D. et al. 2003. Glucocorticoids and inflammation revisited: the state of the art. NIH Clinical Staff Conference. Neuroimmunomodulation 10: 247-260.
2. BAEUERLE, P.A. & D. BALTIMORE. 1988. Activation of DNA-binding activity in an apparently cytoplasmic precursor of the NF-kappa B transcription factor. Cell 53: 211-217.
3. MEDURI, G.U. et al. 2002. Prolonged methylprednisolone treatment suppresses systemic inflammation in patients with unresolving acute respiratory distress syndrome. Evidence for inadequate endogenous glucocorticoid secretion and inflammation-induced immune cell resistance to glucocorticoids. Am. J. Respir. Crit. Care Med. 165: 983-991.
4. KATZENSTRIN, A.L., C.M. BLOOR & A.A. LEIBOW. 1976. Diffuse alveolar damage - the role of oxygen, shock, and related factors. A review. Am. J. Pathol. 85: 209-228.
5. HUDSON, L.D. et al. 1995. Clinical risks for development of the acute respiratory distress syndrome. Am. J. Respir. Crit. Care Med. 151: 293-301.
6. STEINBERG, K.P. & L.D. HUDSON. 2000. Acute lung injury and acute respiratory distress syndrome. The clinical syndrome. Clin. Chest Med. 21: 401-2417, vii.
7. KRAFFT, P. et al. 1996. The acute respiratory distress syndrome: definitions, severity and clinical outcome. An analysis of 101 clinical investigations. Intensive Care Med. 22: 519-529.
8. SLOANE, RJ. et al. 1992. A multicenter registry of patients with acute respiratory distress syndrome. Physiology and outcome. Am. Rev. Respir. Dis. 146: 419-426.
9. MEDURI, G.U. et al. 1994. Corticosteroid rescue treatment of progressive fibroproliferation in late ARDS. Patterns of response and predictors of outcome. Chest 105: 1516-1527.
10. MEDURI, G.U., M. ELTORKY & H.T. WINER-MURAM. 1995. The fibroproliferative phase of late adult respiratory distress syndrome. Semin. Respir. Infect. 10: 154-175.
11. MURRAY, J.F. et al. 1988. An expanded definition of the adult respiratory distress syndrome. Am. Rev. Respir. Dis. 138: 720-723.
12. BONE, R.C. et al. 1989. An early test of survival in patients with the adult respiratory distress syndrome. The PaO2/FIo2 ratio and its differential response to conventional therapy. Prostaglandin E1 Study Group. Chest 96: 849-851.
13. BERNARD, G.R. et al. 1987. High-dose corticosteroids in patients with the adult respiratory distress syndrome. N. Engl. J. Med. 317: 1565-1570.
14. MEDURI, G.U. 1997. Host defense response and outcome in ARDS. Chest 112: 1154-1158.
15. HEADLEY, A.S., E. TOLLEY & G.U. MEDURI. Infections and the inflammatory response in acute respiratory distress syndrome. Chest 111: 1306-1321.
16. COTRAN, R.S., V. KUMAR & S.L. ROBBINS. 1994. Cellular injury and cellular death. In Pathologic Basis of Disease. R.S. Cotran, V. Kumar & S.L. Robbins, Eds.: 1-34. W.B. Saunders. Philadelphia.
17. BROWER, R.G. et al. 2001. Treatment of ARDS. Chest 120: 1347-1367.
18. LEFERING, R. & E.A. NEUGEBAUER. 1995. Steroid controversy in sepsis and septic shock: a meta-analysis. Crit. Care Med. 23: 1294-1303.
19. CRONIN, L. et al. 1995.Corticosteroid treatment for sepsis: a critical appraisal and meta-analysis of the literature. Crit. Care Med. 23: 1430-1439.
20. MEDURI, G.U. 1999. An historical review of glucocorticoid treatment in Sepsis. Disease pathophysiology and the design of treatment investigation. Sepsis 3: 21-38.
21. ASHBAUGH, D.G. & R.V. MAIER. 1985. Idiopathic pulmonary fibrosis in adult respiratory distress syndrome. Diagnosis and treatment. Arch. Surg. 120: 530-535.
22. HOOPER, R.G. & R.A. KEARL. 1990. Established ARDS treated with a sustained course of adrenocortical steroids. Chest 97: 138-143.
23. SHANLEY, T.P. & H.R. WONG. 2001. Signal transduction pathways in acute lung injury: NF-κB and AP-1. In Molecular Biology of Acute Lung Injury. H.R. Wong & T.P. Shanley, Eds.: 1-16. Kluwer. Boston.
24. Ross, S.D. et al. 2000. Attenuation of lung reperfusion injury after transplantation using an inhibitor of nuclear factor-kappaB. Am. J. Physiol. Lung Cell Mol. Physiol. 279: L528-536.
25. LENTSCH, A.B. et al. 1999. Essential role of alveolar macrophages in intrapulmonary activation of NF-kappaB. Am. J. Respir. Cell Mol. Biol. 20: 692-698.
26. CHRISTMAN, J.W., R.T. SADIKOT & T.S. BLACKWELL. 2000. The role of nuclear factor-kappa B in pulmonary diseases. Chest 117: 1482-1487.
27. KARIN, M. & Y. BEN-NERIAH. 2000. Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. Annu. Rev. Immunol. 18: 621-663.
28. BAEUERLE, P.A. & D. BALTIMORE. 1996. NF-kappa B: ten years after. Cell 87: 13-20.
29. YAMAMOTO, Y. & R.B. GAYNOR. 2001. Therapeutic potential of inhibition of the NF-kappaB pathway in the treatment of inflammation and cancer. J. Clin. Invest. 107: 135-142.
30. BARNES, P.J. & M. KARIN. 1997. Nuclear factor-kappa B: a pivotal transcription factor in chronic inflammatory diseases. N. Engl. J. Med. 336: 1066-1071.
31. STEIN, B. et al. 1993. Cross-coupling of the NF-kappa B p65 and Fos/Jun transcription factors produces potentiated biological function. EMBO J. 12: 3879-3891.
32. BAUMANN, H. & J. GAULDIE. 1994. The acute phase response. Immunol. Today 15: 74-80.
33. HEUMANN, D. & M.P. GLAUSER. 1994. Pathogenesis of sepsis. Sci. Med. 1: 28-37.
34. STRIETER, R.M. et al. 2001. Innate immune mechanisms triggering lung injury. In Molecular Biology of Acute Lung Injury. H.R. Wong & T.P. Shanley, Eds.: 17-33. Kluwer. Boston.
35. SCHWARTZ, M.D. et al. 1996. Nuclear factor-kappa B is activated in alveolar macrophages from patients with acute respiratory distress syndrome. Crit. Care Med. 24: 1285-1292.
36. MAUS, U. et al. 1998. Increased proinflammatory cytokine gene expression in alveolar macrophages is associated with changes in NF-kB DNA binding activity in septic ARDS. AJRCCM 157: A459.
37. MOINE, P. et al. 2000. NF-kappaB regulatory mechanisms in alveolar macrophages from patients with acute respiratory distress syndrome. Shock 13: 85-91.
38. CARTER, A.B., M.M. MONICK & G.W. HUNNINGHAKE. 1998. Lipopolysaccharide-induced NF-kappaB activation and cytokine release in human alveolar macrophages is PKC-independent and TK- and PC-PLC- dependent. Am. J. Respir. Cell. Mol. Biol. 18: 384-391.
39. STRIETER, R.M. et al. 1993. Cytokines. 2. Cytokines and lung inflammation: mechanisms of neutrophil recruitment to the lung. Thorax 48: 765-769.
40. VAN DER POLL, T. et al. 1990. Activation of coagulation after administration of tumor necrosis factor to normal subjects. N. Engl. J. Med. 322: 1622-1627.
41. ELIAS, J. A. et al. 1990. Cytokine networks in the regulation of inflammation and fibrosis in the lung. Chest 97: 1439-1445.
42. KING, R.J., M.B. JONES & P. MINOO. 1989. Regulation of lung cell proliferation by polypeptide growth factors. Am. J. Physiol. 257: L23-38.
43. POSTLETHWAITE, A.E. & J.M. SEYER. 1990. Stimulation of fibroblast chemotaxis by human recombinant tumor necrosis factor alpha (TNF-alpha) and a synthetic TNF-alpha 31-68 peptide. J. Exp. Med. 172: 1749-1756.
44. PERLSTEIN, R.S. et al. 1993. Synergistic roles of interleukin-6, interleukin-1, and tumor necrosis factor in the adrenocorticotropin response to bacterial lipopolysaccharide in vivo. Endocrinology 132: 946-952.
45. HERMUS, A.R. & C.G. SWEEP. 1990. Cytokines and the hypothalamic-pituitary-adrenal axis. J. Steroid Biochem. Mol. Biol. 37: 867-871.
46. GALLIN, J.K., I.M. GOLDSTEIN & R. SNYDERMAN. 1988. Overview. In Inflammation: Basic Principles and Clinical Correlates., J.I. Gallin, I.M. Goldstein & R. Snyderman, Eds.: 1-3. Raven Press. New York.
47. CERAMI, A. 1992. Inflammatory cytokines. Clin. Immunol. Immunopathol. 62): S3-10.
48. CHRISTOU, N.V. 1996. Host defense mechanisms of surgical patients. Friend or foe? Arch. Surg. 131: 1136-1140.
49. GUIRAO, X. & S.F. LOWRY. 1996. Biologic control of injury and inflammation: much more than too little or too late. World J. Surg. 20: 431-446.
50. MUNCK, A., P.M. GUYRE & N.J. HOLBROOK. 1984. Physiological functions of glucocorticoids in stress and their relation to pharmacological actions. Endocr. Rev. 5: 25-44.
51. ZUCKERMAN, S.H., J. SHELLHAAS & L.D. BUTLER. 1989. Differential regulation of lipopolysaccharide-induced interleukin 1 and tumor necrosis factor synthesis: effects of endogenous and exogenous glucocorticoids and the role of the pituitary-adrenal axis. Eur. J. Immunol. 19: 301-305.
52. VERMES, I. et al. 1995. Dissociation of plasma adrenocorticotropin and cortisol levels in critically ill patients: possible role of endothelin and atrial natriuretic hormone. J. Clin. Endocrinol. Metab. 80: 1238-1242.
53. HAMMOND, G.L. 1995. Potential functions of plasma steroid-binding proteins. Trends Endocrinol. Metab. 6: 298-304.
54. BAMBERGER, C.M., H.M. SCHULTE & G.P. CHROUSOS. 1996. Molecular determinants of glucocorticoid receptor function and tissue sensitivity to glucocorticoids. Endocr. Rev. 17: 245-261.
55. BAMBERGER, C.M. et al. 1995. Glucocorticoid receptor beta, a potential endogenous inhibitor of glucocorticoid action in humans. J. Clin. Invest. 95: 2435-2441.
56. DIDONATO, J.A., F. SAATCIOGLU, AND M. KARIN. 1996. Molecular mechanisms of immunosuppression and anti-inflammatory activities by glucocorticoids. Am. J. Respir. Crit. Care Med. 154: S11-15.
57. SCHEINMAN, R.I. et al. 1995. Role of transcriptional activation of I kappa B alpha in mediation of immunosuppression by glucocorticoids. Science 270: 283-286.
58. WISSINK, S. et al. 1998. A dual mechanism mediates repression of NF-kappa B activity by glucocorticoids. Mol. Endocrinol. 12: 355-363.
59. WANG, P. et al. 1995. Interleukin (IL)-10 inhibits nuclear factor kappa B (NF kappa B) activation in human monocytes. IL-10 and IL-4 suppress cytokine synthesis by different mechanisms. J. Biol. Chem. 270: 9558-9563.
60. LENTSCH, A.B. et al. 1997. In vivo suppression of NF-kappa B and preservation of I kappa B alpha by interleukin-10 and interleukin-13. J. Clin. Invest. 100: 2443-2448.
61. SHAMES, B.D. et al. 1998. Interleukin-10 stabilizes inhibitory kappaB-alpha in human monocytes. Shock 10: 389-394.
62. HOFFMAN, S.L. et al. 1984. Reduction of mortality in chloramphenicol- treated severe typhoid fever by high-dose dexamethasone. N. Engl. J. Med. 310: 82-88.
63. POPPERS, D.M., P. SCHWENGER & J. VILCEK. 2000. Persistent tumor necrosis factor signaling in normal human fibroblasts prevents the complete resynthesis of I kappa B-alpha. J. Biol. Chem. 275: 29587-29593.
64. SHEPPARD, K.A. et al. 1998. Nuclear integration of glucocorticoid receptor and nuclear factor- kappaB signaling by CREB-binding protein and steroid receptor coactivator-1. J. Biol. Chem. 273: 29291-29294.
65. BARNES, P.J., A.P. GREENING & G.K. CROMPTON. 1995. Glucocorticoid resistance in asthma. Am. J. Respir. Crit. Care Med. 152: S125-140.
66. CHROUSOS, G.P., DETERA-WADLEIGH, S.D. & M. KARL. 1993. Syndromes of glucocorticoid resistance. Ann. Intern. Med. 119: 1113-1124.
67. PRUZANSKI, W. & P. VADAS. 1991. Phospholipase A2 - a mediator between proximal and distal effectors of inflammation. Immunol Today 12: 143-146.
68. MEDURI, G.U. et al. 1991. Fibroproliferative phase of ARDS. Clinical findings and effects of corticosteroids. Chest 100: 943-952.
69. SANTOS, A.A. et al. 1993. Elaboration of interleukin 1-receptor antagonist is not attenuated by glucocorticoids after endotoxemia. Arch. Surg. 128: 138-143; discussion: 143-144.
70. HART, P.H. et al. 1990. Augmentation of glucocorticoid action on human monocytes by interleukin-4. Lymphokine Res. 1990. 9: 147-153.
71. CHROUSOS, G.P. 1995. The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation. N. Engl. J. Med. 1995. 332: 1351-1362.
72. MELBY, J.C. & W.W. SPINK. 1958. Comparative studies on adrenalcortical function and cortisol metabolism in healthy adults and in patients with shock due to infection. J. Clin. Invest. 37: 1791-1798.
73. REINCKE, M. et al. 1993. The hypothalamic-pituitary-adrenal axis in critical illness: response to dexamethasone and corticotropin-releasing hormone. J. Clin. Endocrinol. Metab. 77: 151-156.
74. BRIEGEL, J. et al. 1991. Contribution of cortisol deficiency to septic shock. Lancet 338: 507-508.
75. ANNANE, D. et al. 2000. A 3-level prognostic classification in septic shock based on cortisol levels and cortisol response to corticotropin. JAMA 283: 1038-1045.
76. MEDURI, G.U. & G.P. CHROUSOS. 1998. Duration of glucocorticoid treatment and outcome in sepsis: is the right drug used the wrong way? Chest 114: 355-360.
77. KASS, E.H. & M. FINLAND. 1957. Adrenocortical hormones and the management of infection. Annu. Rev. Med. 8: 1-18.
78. LAMBERTS, S.W. et al. 1992. Cortisol receptor resistance: the variability of its clinical presentation and response to treatment. J. Clin. Endocrinol. Metab. 74: 313-321.
79. LANE, S.J. & T.H. LEE. 1991. Glucocorticoid receptor characteristics in monocytes of patients with corticosteroid-resistant bronchial asthma. Am. Rev. Respir. Dis. 143: 1020-1024.
80. SHER, E.R. et al. 1994. Steroid-resistant asthma. Cellular mechanisms contributing to inadequate response to glucocorticoid therapy. J. Clin. Invest. 93: 33-39.
81. ADCOCK, I.M. et al. 1995. Differences in binding of glucocorticoid receptor to DNA in steroid-resistant asthma. J. Immunol. 154: 3500-3505.
82. NORBIATO, G. et al. 1992. Cortisol resistance in acquired immunodeficiency syndrome. J. Clin. Endocrinol. Metab. 74: 608-613.
83. MOLIJN, G.J. et al. 1995. Differential adaptation of glucocorticoid sensitivity of peripheral blood mononuclear leukocytes in patients with sepsis or septic shock. J. Clin. Endocrinol. Metab. 80: 1799-1803.
84. ALMAWI, W. Y. et al. 1991. Abrogation of glucocorticoid-mediated inhibition of T cell proliferation by the synergistic action of IL-1, IL-6, and IFN-gamma. J. Immunol. 146: 3523-3527.
85. KAM, J.C. et al. 1993. Combination IL-2 and IL-4 reduces glucocorticoid receptor-binding affinity and T cell response to glucocorticoids. J. Immunol. 151: 3460-3466.
86. SPAHN, J.D. et al. 1996. A novel action of IL-13: induction of diminished monocyte glucocorticoid receptor-binding affinity. J. Immunol. 157: 2654-2659.
87. LIU, L.Y. et al. 1993. Changes of pulmonary glucocorticoid receptor and phospholipase A2 in sheep with acute lung injury after high dose endotoxin infusion. Am. Rev. Respir. Dis. 148: 878-881.
88. FAN, J. et al. 1994. Effect of glucocorticoid receptor (GR) blockade on endotoxemia in rats. Circ. Shock 42: 76-82.
89. BAEUERLE, P.A. & V.R. BAICHWAL. 1997. NF-kappa B as a frequent target for immunosuppressive and anti- inflammatory molecules. Adv. Immunol. 65: 111-137.
90. MEDURI, G.U. et al. 1995. Persistent elevation of inflammatory cytokines predicts a poor outcome in ARDS. Plasma IL-1 beta and IL-6 levels are consistent and efficient predictors of outcome over time. Chest 107: 1062-1073.
91. MEDURI, G.U. et al. 1995. Inflammatory cytokines in the BAL of patients with ARDS. Persistent elevation over time predicts poor outcome. Chest 108: 1303-1314.
92. MEDURI, G.U. et al. 1995. Plasma and BAL cytokine response to corticosteroid rescue treatment in late ARDS. Chest 108: 1315-1325.
93. MEDURI, G.U. et al. 1998. Procollagen types I and III aminoterminal propeptide levels during acute respiratory distress syndrome and in response to methylprednisolone treatment. Am. J. Respir. Crit. Care Med. 158: 1432-1441.
94. GOLDEN, E. et al. 2000. Interleukin-8 and Soluble Intercellular adhesion molecule-1 during acute respiratory distress syndrome and in response to prolonged methylprednisolone treatment (Abstr.). Shock 13: 42S.
95. STENTZ, F. et al. 2001. Mechanisms of NF-κB and glucocorticoid receptor (GRα) in activation and regulation of systemic inflammation (SI) in ARDS (Abstr.). Am. J. Respir. Crit. Care Med. 163: A450.
96. HEADLEY, A.S. et al. 2000. Infections, SIRS, and CARS during ARDS and in response to prolonged glucocorticoid treatment (Abstr.). Am. J. Respir. Crit. Care Med. 161: A378.
97. BERNARD, G.R. et al. 1995. Quantification of organ failure for clinical trials. Am. J. Respir. Crit. Care Med. 151: A323.
98. MEDURI, G.U. et al. 1998. Prolonged methylprednisolone treatment improves lung function and outcome of unresolving ARDS. A randomized, double-blind, placebo-controlled trial. JAMA 280: 159-165.
99. CARRATU, P. et al. 2002. TNF-α and LT-α gene polymorphism in acute respiratory distress syndrome (ARDS) (Abstr.). Am. J. Respir. Crit. Care Med. 165: A474.
100. PUGAZHENTHI, M. et al. 2001. Nuclear uptake of nuclear factor-κB (NF-κB) and glucocorticoid receptor (GR) in lung tissue of patients with unresolving ARDS (U-ARDS) (Abstr.). Am. J. Respir. Crit. Care Med. 163: A452.
101. BRIGHT, G.M. 1995. Corticosteroid-binding globulin influences kinetic parameters of plasma cortisol transport and clearance. J. Clin. Endocrinol. Metab. 80: 770-775.
102. GED, C. et al. 1989. The increase in urinary excretion of 6 beta-hydroxycortisol as a marker of human hepatic cytochrome P450IIIA induction. Br. J. Clin. Pharmacol. 28: 373-387.
103. STANLEY, L.A. et al. 1988. Potentiation and suppression of mouse liver cytochrome P-450 isozymes during the acute-phase response induced by bacterial endotoxin. Eur. J. Biochem. 174: 31-36.
104. SEWER, M.B., D.R. KOOP & E.T. MORGAN. 1997. Differential inductive and suppressive effects of endotoxin and particulate irritants on hepatic and renal cytochrome P-450 expression. J. Pharmacol. Exp. Ther. 280: 1445-1454.
105. CHEN, Y.L. et al. 1992. Effects of interleukin-6 on cytochrome P450-dependent mixed-function oxidases in the rat. Biochem. Pharmacol. 44: 137-148.
106. CHEN, J.Q. et al. 1995. Suppression of the constitutive expression of cytochrome P-450 2C11 by cytokines and interferons in primary cultures of rat hepatocytes: comparison with induction of acute-phase genes and demonstration that CYP2C11 promoter sequences are involved in the suppressive response to interleukins 1 and 6. Mol. Pharmacol. 47: 940-947.
107. MORGAN, E.T. et al. 1994. Selective suppression of cytochrome P-450 gene expression by interleukins 1 and 6 in rat liver. Biochim. Biophys. Acta 1219: 475-83.
108. SHEDLOFSKY, S.I. et al. 1994. Endotoxin administration to humans inhibits hepatic cytochrome P450-mediated drug metabolism. J. Clin. Invest. 94: 2209-2214.
109. PARENT, C. et al. 1992. Effect of inflammation on the rabbit hepatic cytochrome P-450 isoenzymes: alterations in the kinetics and dynamics of tolbutamide. J. Pharmacol. Exp. Ther. 261: 780-787.
110. MONSHOUWER, M. et al. 1995. Selective effects of a bacterial infection (Actinobacillus pleuropneumoniae) on the hepatic clearances of caffeine, antipyrine, paracetamol, and indocyanine green in the pig. Xenobiotica 25: 491-499.
111. PERLMUTTER, D.H. et al. 1986. Cachectin/tumor necrosis factor regulates hepatic acute-phase gene expression. J. Clin. Invest. 78: 1349-1354.
112. NADAI, M. et al. 1993. Alterations in pharmacokinetics and protein binding behavior of cefazolin in endotoxemic rats. Antimicrob. Agents Chemother. 37: 1781-1785.
113. WANG, L. et al. 1993. The effect of lipopolysaccharide on the disposition of xanthines in rats. J. Pharm. Pharmacol. 45: 34-38.
114. PUGEAT, M. et al. 1989. Decreased immunoreactivity and binding activity of corticosteroid-binding globulin in serum in septic shock. Clin. Chem. 35: 1675-1679.
115. MELBY, J.C., R.H. EGDAHL & W.W. SPINK. 1960. Secretion and metabolism of cortisol after injection of endotoxin. J. Lab. Clin. Med. 56: 50-62.
116. PERROT, D. et al. 1993. Hypercortisolism in septic shock is not suppressible by dexamethasone infusion. Crit. Care Med. 21: 396-401.
117. SAVU, L. et al. 1981. Serum depletion of corticosteroid binding activities, an early marker of human septic shock. Biochem. Biophys. Res. Commun. 102: 411-419.
118. VADAS, P. et al. 1988. Concordance of endogenous cortisol and phospholipase A2 levels in gram-negative septic shock: a prospective study. J. Lab. Clin. Med. 111(5): 584-590.
119. YATES, C.R. et al. 2001. Time-variant increase in methylprednisolone clearance in patients with acute respiratory distress syndrome: a population pharmocokinetic study. J. Clin. Pharmacol. 41: 1-10.
120. CHAUDHARY, P.M., E.B. MECHETNER & I.B. RONINSON. 1992. Expression and activity of the multidrug resistance P-glycoprotein in human peripheral blood lymphocytes. Blood 80: 2735-2739.
121. DRACH, D. et al. 1992. Subpopulations of normal peripheral blood and bone marrow cells express a functional multidrug resistant phenotype. Blood 80: 2729-2734.
122. VAN KALKEN, C.K. et al. 1993. Cortisol is transported by the multidrug resistance gene product P-glycoprotein. Br. J. Cancer 67: 284-289.
123. FARRELL, R.J. et al. 2002. P-glycoprotein-170 inhibition significantly reduces cortisol and ciclosporin efflux from human intestinal epithelial cells and T lymphocytes. Aliment. Pharmacol. Ther. 16: 1021-1031.
124. YATES, C.R. et al. 2003. Structural determinants of P-glycoprotein- mediated transport of glucocorticoids. Pharm. Res. 20: 1794-1803.
125. HIRSCH-ERNST, K.I. et al. 1998. Induction of mdr1b mRNA and P-glycoprotein expression by tumor necrosis factor alpha in primary rat hepatocyte cultures. J. Cell. Physiol. 176: 506-515.
126. CUFER, T. et al. 2000. Decreased cortisol secretion by adrenal glands perfused with the P-glycoprotein inhibitor valspodar and mitotane or doxorubicin. Anticancer Drugs 11: 303-309.
127. RICKETTS, M.L. et al. 1998. Regulation of 11 beta-hydroxysteroid dehydrogenase type 1 in primary cultures of rat and human hepatocytes. J. Endocrinol. 156: 159-168.
128. JAMIESON, P.M. et al. 1995. 11 beta-Hydroxysteroid dehydrogenase is an exclusive 11 beta-reductase in primary cultures of rat hepatocytes: effect of physicochemical and hormonal manipulations. Endocrinology 136: 4754-4761.
129. JAMIESON, P.M. et al. 2000. 11 beta-Hydroxysteroid dehydrogenase type 1 is a predominant 11 beta-reductase in the intact perfused rat liver. J. Endocrinol. 165: 685-692.
130. GE, R.S. & M.P. HARDY. 2000. Initial predominance of the oxidative activity of type I 11beta-hydroxysteroid dehydrogenase in primary rat Leydig cells and transfected cell lines. J. Androl. 21: 303-310.
131. STEWART, P.M. & Z.S. KROZOWSKI. 1999. 11 beta-Hydroxysteroid dehydrogenase. Vitam. Horm. 57: 249-324.
132. KOTELEVTSEV, Y. et al. 1999. Hypertension in mice lacking 11beta-hydroxysteroid dehydrogenase type 2. J. Clin. Invest. 103: 683-689.
133. SECKL, J.R. & B.R. WALKER. 2001. Minireview: 11beta-hydroxysteroid dehydrogenase type 1 - a tissue-specific amplifier of glucocorticoid action. Endocrinology 142: 1371-1376.
134. ESCHER, G. et al. 1997. Tumor necrosis factor alpha and interleukin 1beta enhance the cortisone/cortisol shuttle. J. Exp. Med. 186: 189-198.
135. STITH, R.D. & R.E. MCCALLUM. 1983. Down regulation of hepatic glucocorticoid receptors after endotoxin treatment. Infect. Immun. 40: 613-621.
136. HUANG, Z.H., H. GAO & R.B. XU. 1987. Study on glucocorticoid receptors during intestinal ischemia shock and septic shock. Circ. Shock 23: 27-36.
137. LI, F. & R.B. XU. 1988. Changes in canine leukocyte glucocorticoid receptors during endotoxin shock. Circ. Shock 26: 99-105.
138. MOLIJN, G.J. et al. 1995. Temperature-induced down-regulation of the glucocorticoid receptor in peripheral blood mononuclear leucocyte in patients with sepsis or septic shock. Clin. Endocrinol. (Oxf.) 43: 197-203.
139. GALIGNIANA, M.D., G. PIWIEN-PILIPUK & J. ASSREUY. 1999. Inhibition of glucocorticoid receptor binding by nitric oxide. Mol. Pharmacol. 55: 317-323.
140. LIU, L.Y. et al. 1993. Changes of pulmonary glucocorticoid receptor and phospholipase A2 in sheep with acute lung injury after high dose endotoxin infusion. Am. Rev. Respir. Dis. 148: 878-881.
141. VERHEGGEN, M.M. et al. 1996. Modulation of glucocorticoid receptor expression in human bronchial epithelial cell lines by IL-1 beta, TNF-alpha and LPS. Eur. Respir. J. 9: 2036-2043.
142. SCHLECHTE, J.A., B.H. GINSBERGN & B.M. SHERMAN. 1982. Regulation of the glucocorticoid receptor in human lymphocytes. J. Steroid Biochem. 16: 69-74.
143. TORNELLO, S. et al. 1982. Regulation of glucocorticoid receptors in brain by corticosterone treatment of adrenalectomized rats. Neuroendocrinology 35: 411-417.
144. SAPOLSKY, R.M., L.C. KREY & B.S. MCEWEN. 1984. Stress down-regulates corticosterone receptors in a site-specific manner in the brain. Endocrinology 114: 287-292.
145. LACROIX, A., G.D. BONNARD & M.E. LIPPMAN. 1984. Modulation of glucocorticoid receptors by mitogenic stimuli, glucocorticoids and retinoids in normal human cultured T cells. J. Steroid Biochem. 21: 73-80.
146. CIDLOWSKI, J.A. & N.B. CIDLOWSKI. 1981. Regulation of glucocorticoid receptors by glucocorticoids in cultured HeLa S3 cells. Endocrinology 109: 1975-1982.
147. SVEC, F. & M. RUDIS. 1981. Glucocorticoids regulate the glucocorticoid receptor in the AtT-20 cell. J. Biol. Chem. 256: 5984-5987.
148. BURNSTEIN, K.L., C.M. JEWELL & J.A. CIDLOWSKI. 1990. Human glucocorticoid receptor cDNA contains sequences sufficient for receptor down-regulation. J. Biol. Chem. 265: 7284-7291.
149. DONG, Y. et al. 1988. Regulation of glucocorticoid receptor expression: evidence for transcriptional and posttranslational mechanisms. Mol. Endocrinol. 2: 1256-1264.
150. HOECK, W., S. RUSCONI & B. GRONER. 1989. Down-regulation and phosphorylation of glucocorticoid receptors in cultured cells. Investigations with a monospecific antiserum against a bacterially expressed receptor fragment. J. Biol. Chem. 264: 14396-14402.
151. ROSEWICZ, S. et al. 1988. Mechanism of glucocorticoid receptor down-regulation by glucocorticoids. J. Biol. Chem. 263: 2581-2584.
152. VEDECKIS, W.V., M. ALI & H.R. ALLEN. 1989. Regulation of glucocorticoid receptor protein and mRNA levels. Cancer Res. 49: 2295s-2302s.
153. BEATO, M., P. HERRLICH & G. SCHUTZ. 1995. Steroid hormone receptors: many actors in search of a plot. Cell 83: 851-857.
154. KARIN, M. 1998. New twists in gene regulation by glucocorticoid receptor: is DNA binding dispensable? Cell 93: 487-490.
155. REICHARDT, H.M. et al. 2001. Repression of inflammatory responses in the absence of DNA binding by the glucocorticoid receptor. EMBO J. 20: 7168-7173.
156. LANE, S.J. & T.H. LEE. 1996. Mononuclear cells in corticosteroid-resistant asthma. Am. J. Respir. Crit. Care Med. 154: S49-51; discussion: S52.
157. ADCOCK, I.M. et al. 1995. Abnormal glucocorticoid receptor-activator protein 1 interaction in steroid-resistant asthma. J. Exp. Med. 182: 1951-1958.
158. LANE, S.J. et al. 1998. Corticosteroid-resistant bronchial asthma is associated with increased c-fos expression in monocytes and T lymphocytes. J. Clin. Invest. 102: 2156-2164.
159. WEBSTER, J.C. et al. 2001. Proinflammatory cytokines regulate human glucocorticoid receptor gene expression and lead to the accumulation of the dominant negative beta isoform: a mechanism for the generation of glucocorticoid resistance. Proc. Natl. Acad. Sci. USA 98: 6865-6870.